6 June, 2024
0 Comments
1 category
medicine
Thursday, June 6, 2024
Chicago Trastuzumab-Deruxtecan delays cancer growth in patients with metastatic, hormone receptor-positive, HER2-low or HER2-ultralow breast cancer that has progressed after endocrine therapy (ET). This is shown by the results of the DESTINY-Breast06 study presented at the 2024 (ASCO) Annual Meeting (Abstract LBA1000). These results could also lead to a shift in the classification and treatment of metastatic breast cancer…
#HER2low #breast #cancer #TrastuzumabDeruxtecan #improves #PFS #without..
Category: Medical Encyclopedia